A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

NCT06768489 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: JNJ-79635322
DRUG: Daratumumab
DRUG: Pomalidomide
DRUG: Lenalidomide

Sponsor

Janssen Research & Development, LLC